GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Gross Profit

PLx Pharma (FRA:1D5A) Gross Profit : €0.05 Mil (TTM As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Gross Profit?

PLx Pharma's gross profit for the three months ended in Sep. 2022 was €-1.09 Mil. PLx Pharma's gross profit for the trailing twelve months (TTM) ended in Sep. 2022 was €0.05 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. PLx Pharma's gross profit for the three months ended in Sep. 2022 was €-1.09 Mil. PLx Pharma's Revenue for the three months ended in Sep. 2022 was €0.39 Mil. Therefore, PLx Pharma's Gross Margin % for the quarter that ended in Sep. 2022 was -278.21%.

PLx Pharma had a gross margin of -278.21% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage


PLx Pharma Gross Profit Historical Data

The historical data trend for PLx Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Gross Profit Chart

PLx Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.66 0.51 0.03 3.01

PLx Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.30 0.62 0.83 -0.32 -1.09

Competitive Comparison of PLx Pharma's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Gross Profit falls into.



PLx Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

PLx Pharma's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )=Revenue - Cost of Goods Sold
=7.264 - 4.252
=3.01

PLx Pharma's Gross Profit for the quarter that ended in Sep. 2022 is calculated as

Gross Profit (Q: Sep. 2022 )=Revenue - Cost of Goods Sold
=0.39 - 1.475
=-1.09

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.05 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

PLx Pharma's Gross Margin % for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=-1.09 / 0.39
=-278.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


PLx Pharma  (FRA:1D5A) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PLx Pharma had a gross margin of -278.21% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage


PLx Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma (FRA:1D5A) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines